Allo-HSCT cures adult with congenital dyserythropoietic anemia

David Levy
Photo from David Levy
Physicians have reported what they believe is the first case of an allogeneic hematopoietic stem cell transplant (allo-HSCT) curing an adult with congenital dyserythropoietic anemia (CDA). The patient, David Levy, was previously transfusion-dependent and suffered from iron overload, severe pain, and other adverse effects of... [Read Article]

MRD predicts outcome of HSCT in ALL, study suggests

HSCT preparation
Photo by Chad McNeeley
Minimal residual disease (MRD) measurements before and after hematopoietic stem cell transplant (HSCT) can help predict outcomes in patients with childhood acute lymphoblastic leukemia (ALL), according to researchers. Their work also suggests several other factors can be used to predict event-free survival (EFS) in this patient population,... [Read Article]

MSC product granted fast track designation

Mesenchymal stem cells
The US Food and Drug Administration (FDA) has granted fast track designation to a mesenchymal stem cell (MSC) product, MSC-100-IV, as a treatment for children with steroid-refractory acute graft-vs-host disease (aGVHD). MSC-100-IV consists of human MSCs derived from donor bone marrow and expanded in culture. Fast track designation has the potential... [Read Article]

Genetic variants linked to HSCT outcomes in ALL

Genome analysis
Image courtesy of the
National Institute of
General Medical Sciences
Results of a genome-wide association study suggest that several genetic variants are associated with outcomes of allogeneic hematopoietic stem cell transplant (HSCT) in patients with acute lymphoblastic leukemia (ALL). Investigators identified several single-nucleotide polymorphisms (SNPs) in ALL patients and their unrelated... [Read Article]

Study advances precision opioid dosing for mucositis

Child with cancer
Photo by Bill Branson
A pilot study to determine the burden of mucositis in pediatric patients undergoing hematopoietic stem cell transplant (HSCT) found that more than 50% of patients required a change in their opioids either for toxicity or lack of efficacy. Investigators also observed that patients’ genotypes were associated with... [Read Article]